Drug manufacturer PharmAthene Inc. is seeking Delaware Court of Chancery approval of a more than $194.5 million judgment against a company with which it developed a smallpox vaccine.
PharmAthene’s proposed order resolving the eight-year-old dispute with Siga Technologies Inc. comes days after Vice Chancellor Donald F. Parsons Jr. reduced PharmAthene’s initial request for contract expectation damages from about $140 million to $113 million. The judge ordered the parties give a proposed final order and judgment in the case based on his Jan. 7 calculation of the expectation damages.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
